AI Image
FDA approves once-daily Parkinson’s pill (Juvmo) built on decades of work by husband-and-wife team
The Brighter Side of News • • health
Key Points:
- The FDA approved Juvmo (tavapadon), a once-daily pill targeting D1 and D5 dopamine receptors, to treat movement symptoms in adults with Parkinson’s disease, either alone or with levodopa.
- Clinical trials (TEMPO-1, TEMPO-3) showed Juvmo improved motor function in early Parkinson’s and added about 1.1 hours of daily "on" time without troublesome involuntary movements when combined with levodopa.
- Juvmo represents a novel approach by selectively activating D1-like receptors, differing from most existing treatments that target D2/D3 receptors, but it does not slow disease progression or nerve-cell loss.
- Long-term open-label data suggest many patients maintained stable levodopa dosing while on Juvmo, though this does not confirm disease-modifying effects, and safety concerns include low blood pressure, hallucinations, and compulsive behaviors.
- The drug’s approval expands symptomatic treatment options, but further research is needed to assess benefits in advanced Parkinson’s and potential cognitive effects.
